Angiotensin-(1-7) as an antihypertensive, antifibrotic target. Curr Hypertens Rep 2008 Jun;10(3):227-32
Date
09/04/2008Pubmed ID
18765095DOI
10.1007/s11906-008-0043-9Scopus ID
2-s2.0-56349087447 (requires institutional sign-in at Scopus site) 35 CitationsAbstract
Over the past two decades, enormous progress has been made in understanding the possible physiological significance of alternate renin-angiotensin system processing pathways and angiotensin fragments, such as angiotensin (Ang)-(1-7). Evidence from in vivo and ex vivo studies in humans and various animal models suggests a possible role for this heptapeptide in blood pressure regulation, although the mechanisms involved are most likely indirect, involving some combination of bradykinin and nitric oxide signaling. In contrast, a growing body of in vivo and in vitro evidence supports direct cardioprotective (antihypertrophic, antifibrotic) actions of Ang-(1-7). Here, we review key studies investigating the blood pressure and tissue-protective roles of Ang-(1-7), and summarize potential genomic and pharmacologic therapeutic strategies previously advanced by our group and others.
Author List
Katovich MJ, Grobe JL, Raizada MKAuthor
Justin L. Grobe PhD Professor in the Physiology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Angiotensin IAntihypertensive Agents
Blood Pressure
Bradykinin
Cardiotonic Agents
Fibrinolytic Agents
Humans
Hypertension
Nitric Oxide
Peptide Fragments
Receptors, Cell Surface
Renin-Angiotensin System
Signal Transduction
